Initial Beneficial Ownership · 3
Damora Therapeutics, Inc.
DMRANASDAQEQUITYCurrent
Initial Beneficial Ownership
Structured filing — 3
ownership.xml
Filing details
- Report period
- 2026-08-12
- Issuer
- Damora Therapeutics, Inc.
- Issuer CIK
- 0001800315
- Trading symbol
- DMRA
- No securities owned
- Checked
Reporting owner 1
- Name
- Cheng Andrew
- Reporting owner CIK
- 0001778307
- Relationship
- Director
- Address
- C/O DAMORA THERAPEUTICS, INC., 221 CRESCENT ST., BLDG 23, STE 105, WALTHAM, MA, 02453
Remarks
Exhibit 24 - Power of Attorney
Signature 1
- Signed
- /s/ Garrett Winslow
- Date
- 2026-08-13
Filed exhibits
- EX-24 ↗dmra-ex24.htm
Company context
Damora Therapeutics is an innovative biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. We are advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. With multiple programs with best-in-class potential on track to enter clinical development in 2026, our goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. For more information, visit www.damoratx.com or follow us on LinkedIn.